{"id":1016877,"date":"2026-11-04T23:12:49","date_gmt":"2026-11-05T04:12:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/"},"modified":"2026-11-04T23:12:49","modified_gmt":"2026-11-05T04:12:49","slug":"enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/","title":{"rendered":"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study<\/b><\/p>\n<p class=\"bwalignc\"><i>Findings support central nervous system penetration and functional brain activity differentiated from the classic psychedelic DMT<\/i><\/p>\n<p class=\"bwalignc\"><i>Results support use of qEEG as a potential pharmacodynamic biomarker in first-in-human development<\/i><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nEnveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced results from a quantitative electroencephalography (qEEG) study of its lead candidate, EB-003, in mice. The study demonstrated modulation of brain activity in prefrontal and parietal regions of the cortex, providing functional evidence of central nervous system penetration and revealing a neurophysiological profile differentiated from dimethyltryptamine (DMT), a classic hallucinogenic psychedelic.<\/p>\n<p>\nThe study evaluated EB-003 in mice using continuous qEEG recording across a broad range of brain-wave frequency bands, with DMT included as a comparator. The study achieved its primary objective of establishing a translational pharmacodynamic measure of EB-003\u2019s effects on cortical brain-wave oscillations. Additionally, in the study, DMT induced notable epileptic-like EEG activity and acute body spasms. EB-003 did not elicit similar findings, indicating a more favorable neurophysiological profile.<\/p>\n<p>\nQuantitative EEG measures the brain\u2019s electrical activity across different frequency bands, and maps them across brain regions, providing a method to characterize how a drug affects brain electrical function. The results generated in this study strengthen the rationale for evaluating qEEG in EB-003\u2019s planned first-in-human program, where it could complement safety and pharmacokinetic assessments and help inform dose selection for later studies.<\/p>\n<p>\n\u201cThese results demonstrate EB-003 induces measurable activity in relevant brain regions with a profile differentiated from DMT, providing additional evidence of EB-003\u2019s unique pharmacological profile and mechanism of action,\u201d said Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric Biosciences. \u201cThe research has also identified qEEG as a suitable objective biomarker that we can utilize in upcoming human studies. As we advance toward our planned Phase 1 clinical trial of EB-003, the ability to correlate drug exposure to changes in brain activity on qEEG could help us identify biologically active doses and make more informed decisions for subsequent trials.\u201d<\/p>\n<p>\nKey findings included:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Functional brain activity:<\/b> EB-003 modulated brain-wave oscillations in prefrontal and parietal cortical regions, providing an objective measure of its effects on brain function.\n<\/li>\n<li><b>Differentiated neurophysiological signature:<\/b> EB-003 produced a brain-wave profile different from DMT, adding a new dimension to the evidence supporting its differentiated pharmacology.\n<\/li>\n<li><b>Favorable safety observations:<\/b> EB-003 did not induce abnormal epileptiform brain activity or disruptive sedation patterns. These findings complement the promising safety profile observed previously in animal toxicology studies.\n<\/li>\n<li><b>A potential bridge to clinical development:<\/b> The findings of this study support evaluation of qEEG as a pharmacodynamic biomarker in first-in-human trials, with the potential to correlate drug exposure to functional effects in the brain.\n<\/li>\n<\/ul>\n<p>\nEB-003, Enveric\u2019s lead neuroplastogen candidate, is designed to engage both 5-HT<sub>2A<\/sub> and 5-HT<sub>1B<\/sub> receptors with the potential to promote neuroplasticity without hallucinogenic effects. The new qEEG findings expand the preclinical evidence supporting EB-003\u2019s differentiated profile as the Company advances toward clinical development.<\/p>\n<p><b>About Enveric Biosciences<\/b><\/p>\n<p>\nEnveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric\u2019s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT<sub>2A<\/sub> and 5-HT<sub>1B<\/sub> receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.<\/p>\n<p>\nFor more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com&amp;esheet=54634430&amp;newsitemid=20261104996165&amp;lan=en-US&amp;anchor=www.enveric.com&amp;index=1&amp;md5=287c8f99e12086ed700393e54b140ef8\">www.enveric.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information, including, without limitation, statements regarding the interpretation and potential significance of the preclinical qEEG study results; the potential central nervous system, neuroplastogenic, non-hallucinogenic, therapeutic or other properties of EB-003; the potential use of qEEG as a pharmacodynamic biomarker; the potential ability to correlate drug exposure with changes in brain activity, identify biologically active doses or inform dose selection; the timing or completion of IND-enabling studies or an IND submission; the initiation, design, timing or results of a planned Phase 1 clinical trial; and Enveric\u2019s development plans and regulatory strategy for EB-003. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as \u201cplans,\u201d \u201cexpects\u201d or \u201cdoes not expect,\u201d \u201cproposes,\u201d \u201cbudgets,\u201d \u201cexplores,\u201d \u201cschedules,\u201d \u201cseeks,\u201d \u201cestimates,\u201d \u201cforecasts,\u201d \u201cintends,\u201d \u201canticipates\u201d or \u201cdoes not anticipate,\u201d or \u201cbelieves,\u201d or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND application to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain sufficient future funding for product development, clinical development activities, working capital and other operating expenses on commercially reasonable terms, or at all; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric\u2019s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.<\/p>\n<p>\nA discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric\u2019s filings with the Securities and Exchange Commission, including Enveric\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261104996165\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261104996165\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftiberend.com%2F&amp;esheet=54634430&amp;newsitemid=20261104996165&amp;lan=en-US&amp;anchor=Tiberend+Strategic+Advisors%2C+Inc.&amp;index=2&amp;md5=e87df467b4243fc5498ef4f3b91ac229\">Tiberend Strategic Advisors, Inc.<br \/>\n<\/a><br \/>David Irish<br \/>\n<br \/>(231) 632-0002<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:dirish@tiberend.com\">dirish@tiberend.com<\/a><\/p>\n<p><b>Media Relations<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftiberend.com%2F&amp;esheet=54634430&amp;newsitemid=20261104996165&amp;lan=en-US&amp;anchor=Tiberend+Strategic+Advisors%2C+Inc.&amp;index=3&amp;md5=4a36b84ff8efeb0c0e7065d68ec35e45\">Tiberend Strategic Advisors, Inc.<br \/>\n<\/a><br \/>Casey McDonald<br \/>\n<br \/>(646) 577-8520<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cmcdonald@tiberend.com\">cmcdonald@tiberend.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Canada Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Mental Health Research Neurology Clinical Trials Biotechnology Health Pharmaceutical Other Science Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261104996165\/en\/2957569\/3\/Enveric.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study Findings support central nervous system penetration and functional brain activity differentiated from the classic psychedelic DMT Results support use of qEEG as a potential pharmacodynamic biomarker in first-in-human development CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced results from a quantitative electroencephalography (qEEG) study of its lead candidate, EB-003, in mice. The study demonstrated modulation of brain activity in prefrontal and parietal regions of the cortex, providing functional evidence of central nervous system penetration and revealing a neurophysiological profile differentiated from dimethyltryptamine (DMT), a classic hallucinogenic psychedelic. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1016877","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study Findings support central nervous system penetration and functional brain activity differentiated from the classic psychedelic DMT Results support use of qEEG as a potential pharmacodynamic biomarker in first-in-human development CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced results from a quantitative electroencephalography (qEEG) study of its lead candidate, EB-003, in mice. The study demonstrated modulation of brain activity in prefrontal and parietal regions of the cortex, providing functional evidence of central nervous system penetration and revealing a neurophysiological profile differentiated from dimethyltryptamine (DMT), a classic hallucinogenic psychedelic. The &hellip; Continue reading &quot;Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T04:12:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study\",\"datePublished\":\"2026-11-05T04:12:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/\"},\"wordCount\":1171,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/\",\"name\":\"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-05T04:12:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/","og_locale":"en_US","og_type":"article","og_title":"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study - Market Newsdesk","og_description":"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study Findings support central nervous system penetration and functional brain activity differentiated from the classic psychedelic DMT Results support use of qEEG as a potential pharmacodynamic biomarker in first-in-human development CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced results from a quantitative electroencephalography (qEEG) study of its lead candidate, EB-003, in mice. The study demonstrated modulation of brain activity in prefrontal and parietal regions of the cortex, providing functional evidence of central nervous system penetration and revealing a neurophysiological profile differentiated from dimethyltryptamine (DMT), a classic hallucinogenic psychedelic. The &hellip; Continue reading \"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T04:12:49+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study","datePublished":"2026-11-05T04:12:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/"},"wordCount":1171,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/","name":"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-05T04:12:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104996165r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-reports-differentiated-brain-activity-profile-for-eb-003-in-preclinical-qeeg-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1016877"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016877\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1016877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1016877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1016877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}